STEPHEN DAVIS - 04 Jan 2022 Form 4 Insider Report for BELLICUM PHARMACEUTICALS, INC

Role
Director
Signature
/s/ Richard A. Fair, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
04 Jan 2022
Net transactions value
$0
Form type
4
Filing time
06 Jan 2022, 08:31:41 UTC
Previous filing
23 Dec 2021
Next filing
10 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLCM Common Stock Options Exercise $0 +18,715 $0.000000 18,715 04 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLCM Restricted Stock Units Options Exercise $0 -18,715 -100% $0.000000* 0 04 Jan 2022 Common Stock 18,715 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock.
F2 The RSUs vest in full upon the one year anniversary of grant date on January 4, 2021.